Cutting the diagnosis time for urinary tract infections (UTIs) to just 15 minutes, and recommending targeted antibiotics within 30, Sysmex’s PA-100 AST System is driving a new era of efficient, precision care. Backed by an economic analysis in Spain and winner of the £8 million Longitude Prize, the system is reshaping the global response to antimicrobial resistance.
Sysmex’s latest diagnostic innovation, the PA-100 AST System, is redefining how uncomplicated UTIs are diagnosed and managed. Combining state-of-the-art nanofluidic engineering with rapid antimicrobial susceptibility testing (AST), the system delivers comprehensive, actionable results in just 45 minutes. This leap in diagnostic speed allows healthcare professionals to act quickly and effectively, providing patients with tailored treatment based on real-time evidence.
The global impact of UTIs
With more than 400 million cases reported annually, UTIs remain a widespread health concern. Prolonged diagnostic processes and empirical use of antibiotics contribute to treatment inefficiencies and fuel antimicrobial resistance (AMR). Sysmex’s PA-100 AST System, boasting 84% sensitivity and 99% specificity, enables timely, accurate treatment decisions while promoting responsible antibiotic use — a vital step in addressing the AMR challenge.
Alain Baverel, President & CEO Sysmex Europe SE, remarked,
“The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”
Modelling forecasts cost savings for Spain’s healthcare system
According to newly released projections, introducing the PA-100 AST System across Spain’s public health facilities could generate substantial financial savings. The model estimates that if adopted nationally, the system could save approximately €323 million in its first year. These savings are expected to grow over time, driven by decreased hospitalisations, fewer complications, and a reduction in lost productivity.
Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented,
“By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”
Prestigious award underlines the system’s importance
In recognition of its breakthrough potential, the PA-100 AST System was awarded the Longitude Prize — an £8 million honour celebrating innovations that confront the AMR crisis head-on. The accolade highlights the system’s value in improving patient outcomes and transforming antibiotic stewardship globally.
Fast-track diagnostics in a palm-sized device
Utilising an ultra-compact, smartphone-sized cartridge, the PA-100 AST System detects bacteriuria in 15 minutes and pinpoints effective antibiotic treatments within the next 30. This speed empowers clinicians to act fast, reducing delays, complications and reliance on unnecessary medications.
